1. Faik Orucov*, MD, Joseph Frucht-Pery, MD, David Landau, MD, Eyal Strassman, MD, Abraham Solomon, MD Clinical outcome of thin corneas after laser in situ keratomileusis *Refractive Surgery Department, Istanbul Surgery Hospital Istanbul, Turkey Hadassah University Hospital, Jerusalem, Israel Authors have no financial interests in any of the mentioned products or companies

2. PURPOSE To evaluate the clinical outcome of laser in situ keratomileusis (LASIK) for the treatment of myopia with thin corneas.

3. SETTING: Hadassah Optimal Laser Center,Jerusalem, Israel Retrospective study N: 193 eyes Preoperative CCT<498 microns Calculated RST ≤ 250 microm F/U : at least one year Exclusion criteria ; - incomplete documentation - lost to follow-up METHODS

4. RESULTS N/% No of patients 193/100 Sex Female (%) 113/ 58.5 Male 80/ 41.5 Eye Right (%) 96/ 49.7 Left 97/ 50.3 Type of treatment (%) Conventional 75/38.9 Customized 118/61.1 Patient characteristics & Preoperative data SE (Mean) -4.03±1.56 Range -0.94-8.25 D BCVA 1.00±0.09 Range 0.50-1.20 CCT 484.83±10.32 Range 455-497 mm OZ 5.6±0.39 mm Range 4.50-7.0 mm Ablation 60.99±15.57 Range 26-96 Residual Stromal bed 264.5±12.85 Range 250-298 Follow up 18.47±10.36 Range 12-72 months

5. RESULTS Distribution of preoperative central corneal thickness CCT 484.83±10.32 Range 455-497 mm

6. K1 44.88±1.64 D Range 41.0-49.0 D K2 43.94±1.82 Range 39.30-47.73 Dk 0.91±0.80 Range 0.0-5.40 I-S Value 0.84±0.33 Range 0.40-1.70 Posterior float 0.032±0.009 Range 0.01-0.060 Topographic values & The predictability of the procedures Scattergram showing achieved versus attempted correction. RESULTS

7. Postoperative data. Last visit (~18 months) UCVA 0.91±0.25 Range 0.20-1.50 SE -0.27±0.48 Range -1.88+0.50 BCVA 1.03±0.18 Range 0.60-1.50 Safety index 1.04±0.14 Efficacy index 0.92±0.24 No signs of ectasia RESULTS

8. CONCLUSION  LASIK was safe in patients with thin corneas and myopia.  More studies with longer follow-up are needed to elucidate further the safety of the LASIK in thin corneas.